Margolis R N
Department of Anatomy, Howard University Cancer Center, Washington, D.C.
Life Sci. 1987 Dec 14;41(24):2615-22. doi: 10.1016/0024-3205(87)90275-x.
The chronically hyperinsulinemic Zucker fatty rat, with peripheral insulin resistance and glucose intolerance, represents a model of noninsulin dependent diabetes mellitus (NIDDM). These animals have elevated hepatic glycogen levels. Hepatic levels of synthase phosphatase and phosphorylase phosphatase, which are diminished in the IDDM rat, were markedly increased in the obese rats. Glyburide, a sulfonylurea used in treatment of NIDDM, resulted in reduced levels of glycemia and increased insulin levels in Zucker rats. Hepatic glycogen levels were increased, as was the activation of glycogen synthase, although there were no effects of drug administration on synthase phosphatase or phosphorylase phosphatase activities. G6P levels were increased by glyburide in lean rats but not in obese animals. These effects of glyburide on liver glycogen metabolism are accounted for via potentiation of the glycogenic effects of insulin.
慢性高胰岛素血症的Zucker肥胖大鼠存在外周胰岛素抵抗和葡萄糖不耐受,是2型糖尿病(NIDDM)的一种模型。这些动物的肝糖原水平升高。在IDDM大鼠中减少的合酶磷酸酶和磷酸化酶磷酸酶的肝脏水平,在肥胖大鼠中显著增加。格列本脲是一种用于治疗NIDDM的磺脲类药物,可使Zucker大鼠的血糖水平降低,胰岛素水平升高。肝糖原水平增加,糖原合酶的激活也增加,尽管给药对合酶磷酸酶或磷酸化酶磷酸酶活性没有影响。格列本脲可使瘦大鼠的G6P水平升高,但对肥胖动物无此作用。格列本脲对肝脏糖原代谢的这些作用是通过增强胰岛素的糖原生成作用来实现的。